Journal: Journal of Translational Medicine
Article Title: Integrin αvβ3-dependent pathogenic effect and therapeutic effects of DL-N2 combined with EGFR inhibitors in pancreatic adenocarcinoma
doi: 10.1186/s12967-026-07865-0
Figure Lengend Snippet: DL-N2 regulates gene expression and enhances gefitinib-induced inhibition in pancreatic cancer cells. ( A–D ) BxPC-3 and ( E - H ) AsPC-1 cells treated with DL-N2 (10⁻⁹–10⁻⁷ M), gefitinib (10 µM), or their combinations on pancreatic cancer cells. Quantitative real-time PCR analysis of EGFR ( A and E ), PD-L1 ( B and F ), CCND1 ( C and G ), and PCNA ( D and H ) expression. DL-N2 decreased the expression of proliferation- and immune-related genes, with maximal inhibition observed in combination with gefitinib. Data are presented as mean ± SD of four independent experiments ( N = 4). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. gefitinib alone
Article Snippet: Human pancreatic cancer cell lines AsPC-1 and BxPC-3 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).
Techniques: Gene Expression, Inhibition, Real-time Polymerase Chain Reaction, Expressing, Control